Merck KGaG Doesn’t Expect Erbitux Lung Tumor Approval, FTD Says

- Merck KGaA (MRK) says that its Erbitux drug has less than a 50 percent chance of being approved for lung tumor treatment, Financial Times Deutschland reported, citing a briefing for JPMorgan Chase & Co. analysts.

Erbitux is the company’s second biggest seller after its Rebif multiple-sclerosis treatment, according to the newspaper.

To contact the reporters on this story: Karin Matussek in Berlin at kmatussek@bloomberg.net

To contact the editor responsible for this story: Anthony Aarons at aaarons@Bloomberg.net.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.